Table 1.
Patient characteristics of the NRM population
| Early NRM (n = 9) | Late NRM (n = 39) | All NRM (n = 48) | |
|---|---|---|---|
| Age, y | |||
| Median (range) | 73 (30-76) | 66 (41-79) | 67 (61-73) |
| ≥65, n (%) | 8 (88.9) | 22 (57.9) | 30 (63.8) |
| ≥70, n (%) | 5 (55.6) | 14 (35.9) | 19 (39.6) |
| Male sex, n (%) | 4 (44.4) | 25 (64.1) | 29 (60.4) |
| Diabetes, n (%) | 0 | 11 (28.9) | 11 (23.4) |
| ECOG PS, n (%) | |||
| 0-1 | 4 (44.4) | 30 (85.7) | 34 (77.3) |
| ≥2 | 5 (55.6) | 5 (14.3) | 10 (22.7) |
| Histology | |||
| DLBCL, n (%) | 6 (66.7) | 24 (61.5) | 30 (62.5) |
| PMBL, n (%) | 0 | 2 (5.1) | 2 (4.2) |
| HGBL, n (%) | 0 | 0 | 0 |
| tFL, n (%) | 1 (11.1) | 11 (28.2) | 12 (25.0) |
| Other, n (%) | 2 (22.2) | 2 (5.1) | 4 (8.3) |
| aaIPI, n (%) | |||
| 0 | 0 | 2 (5.6) | 2 (4.8) |
| 1 | 1 (16.7) | 12 (33.3) | 13 (31.0) |
| 2 | 4 (66.7) | 19 (52.8) | 23 (54.8) |
| 3 | 1 (16.7) | 3 (8.3) | 4 (9.5) |
| Elevated LDH level at lymphodepletion, n (%) | 8 (88.9) | 17 (45.9) | 25 (54.3) |
| Elevated ferritin level at lymphodepletion, n (%) | 4 (50.0) | 25 (67.6) | 29 (64.4) |
| Hypogammaglobulinemia < 5 g/L at lymphodepletion, n (%) | 4 (100) | 13 (48.1) | 17 (54.8) |
| Prior treatments | |||
| Number of prior lines, median (range) | 2 (2-5) | 3 (2-9) | 3 (2-9) |
| ASCT, n (%) | 0 | 14 (35.9) | 14 (29.2) |
| Allo-SCT, n (%) | 0 | 1 (2.6) | 1 (2.1) |
| Bridging therapy administered, n (%) | |||
| No bridging | 0 | 3 (8.8) | 3 (7.0) |
| Response to bridging (PR or CR) | 0 | 12 (35.3) | 12 (20.9) |
| No response to bridging (SD or PD) | 9 (100) | 19 (55.8) | 28 (65.1) |
| CAR T-cell product | |||
| Axi-cel, n (%) | 4 (44.4) | 27 (69.2) | 31 (64.6) |
| Tisacel, n (%) | 5 (55.6) | 12 (30.8) | 17 (35.4) |
| CRS, n(%) | |||
| Any grade | 9 (100) | 34 (87.2) | 43 (89.6) |
| Grade ≥3 | 6 (66.7) | 7 (17.9) | 13 (27.1) |
| ICANS, n (%) | |||
| Any grade | 6 (66.7) | 24 (61.5) | 30 (62.5) |
| Grade ≥3 | 4 (44.4) | 11 (28.2) | 15 (31.3) |
allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; CR, complete response; DLBCL, diffuse large B-cell lymphoma; HGBL, high-grade B-cell lymphoma; PD, progressive disease; PMBL, primary mediastinal B-cell lymphoma; tFL, transformed follicular lymphoma; PR, partial response; SD, stable disease.